Transmedics Group Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $668.5M+51.4% YoYTTM through 30 Jun 2026
Net Income $151.7M+327.8% YoYTTM through 30 Jun 2026
Free Cash Flow $79MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 59.9% |
| EBITDA Margin | 17.7% |
| Operating Margin | 17.9% |
| Net Margin | 22.7% |
Returns
40.2%ROE
17.8%ROA
30.3%ROIC
Balance Sheet Health
Debt / Equity1.06x
Current Ratio7.14x
Net Debt$14M
Cash & Equivalents$491.1M
Quality Metrics
Altman Z-Score2.78
Piotroski F-Score4 / 9
FCF Margin11.8%
Rule of 4022.8
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $605.5M
Diluted EPS$3.86TTMFY2025: $4.69
Dividend
No dividend
Capital Allocation
R&D Spend$92.5M
Capex Intensity10.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Net Product Revenue | $372.4M | +36.0% | |
| Service Revenue | $233.1M | +39.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.